版本:
中国

BRIEF-Janssen receives Health Canada approval of Darzalex by priority review

April 17 Johnson & Johnson

* Receives Health Canada approval of Darzalex® (daratumumab) by priority review for patients with multiple myeloma who have had at least one prior therapy

* Janssen Inc - data from two Phase 3 studies supported new approval of darzalex

* Janssen Inc - due to "high" unmet medical need for multiple myeloma patients, darzalex was granted priority review by Health Canada for submission Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐